Tiotropium bromide is under clinical development by Boehringer Ingelheim International and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Tiotropium bromide’s likelihood of approval (LoA) and phase transition for Bronchopulmonary Dysplasia took place on 17 Nov 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Tiotropium bromide Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Tiotropium bromide overview

Tiotropium bromide (Spiriva / Spiriva Respimat / Favint / Favint Respimat / Favynd / Srivasso / Spiriva Handihaler / Forvent) is an anticholinergic agent and bronchodilator. It is formulated as capsules, powder, solution for inhalational route of administration. It is indicated for the treatment of bronchospasm associated with chronic obstructive pulmonary disease, chronic bronchitis and emphysema. Spiriva Respimat is also indicated for the long-term, once-daily, maintenance treatment of asthma in patients 6 years of age and older.

It is under development for the treatment of bronchopulmonary dysplasia and was also under development for the treatment of cystic fibrosis.

Boehringer Ingelheim International overview

Boehringer Ingelheim International (Boehringer), a subsidiary of CH Boehringer Sohn AG & Co KG, is a pharmaceutical company that develops, manufactures and markets of pharmaceuticals, parasiticides, vaccines and therapeutics for unmet medical needs. It offers a wide range of products including human diseases, animal health care products and biopharmaceuticals. The company’s products are used for the treatment central nervous system disorders, cardiometabolic diseases, respiratory diseases, cancer, immunology, and retinal diseases among others. It also offers animal healthcare products for Swine, Ruminant, Poultry, Horses, Pets etc. It operates facilities for manufacture pharmaceuticals and medical products. Boehringer is headquartered in Ingelheim am Rhein, Rheinland-Pfalz, Germany.

Quick View Tiotropium bromide LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Tiotropium bromide
Administration Pathway
  • Inhalational
Therapeutic Areas
  • Respiratory
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.